CDK9-IN-40

• Description:

  CDK9-IN-40 is a potent and orally active CDK9 inhibitor with an IC50 of 5.5 nM. CDK9-IN-40 shows high selectivity for CDK9 versus CDK1, CDK2, CDK4, and CDK6, respectively. CDK9-IN-40 can arrest cell cycle, induce cell apoptosis and inhibit tumor growth. CDK9-IN-40 exhibits strong anti-cancer activity[1].

• UNSPSC:

  12352005

• Target:

  Apoptosis; CDK

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Smiles:

  CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC(N4CCC5=C(SC(N)=N5)C4)=CC=N3

• Molecular Formula:

  C21H26N8S

• Molecular Weight:

  422.55

• References & Citations:

  [1]Chen L et al. Discovery and optimization of novel tetrahydrothiazolopyridine-based pyrimidines as highly potent cyclin-dependent kinase 9 (CDK9) inhibitors. Eur J Med Chem. 2025 Jun 14;296:117875. doi: 10.1016. https://pubmed.ncbi.nlm.nih.gov/40544651/|[2]Chen L et al. Discovery and optimization of novel tetrahydrothiazolopyridine-based pyrimidines as highly potent cyclin-dependent kinase 9 (CDK9) inhibitors. Eur J Med Chem. 2025 Jun 14;296:117875. doi: 10.1016.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  CDK9